Lupin Ltd

💊 Lupin Launches Generic Dapagliflozin/Metformin XR Tablets in the U.S.

- Lupin Limited launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States on April 22, 2026.

- The tablets are available in four dosage strengths: 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg.

- The product is bioequivalent to AstraZeneca's Xigduo® XR and received approval from the U.S. FDA under an Abbreviated New Drug Application.

- Lupin is a global pharmaceutical company headquartered in Mumbai, India, with over 24,000 employees and operations in over 100 markets.